Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kamel Laribi

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Blood|February 18, 2021
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.
Blood|October 25, 2017
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphomaThierry Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Hematological Oncology|July 12, 2025
Impact of Body Composition on Treatment Toxicity and Outcomes in Patients With Primary Mediastinal Large B-Cell LymphomaJuliette Penichoux, Pierre Decazes, Cédric Rossi, et al.
Hematological Oncology|July 5, 2022
Isolated intraocular relapses of primary cerebral lymphomas: An LOC network studyNadia Younan, Carole Soussain, Sylvain Choquet, et al.
Nature Communications|August 9, 2024
Blinatumomab after R-CHOP bridging therapy for patients with Richter transformation: a phase 2 multicentre trialRomain Guièze, Loïc Ysebaert, Damien Roos-Weil, et al.
American Journal of Hematology|June 20, 2024
Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatmentSylvain Garciaz, Pierre-Yves Dumas, Sarah Bertoli, et al.
Blood|February 18, 2021
BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemiaCharles Herbaux, Christoph Kornauth, Stéphanie Poulain, et al.
British Journal of Haematology|April 19, 2022
A randomised phase II study of azacitidine (AZA) alone or with Lenalidomide (LEN), Valproic acid (VPA) or Idarubicin (IDA) in higher-Risk MDS or low blast AML: GFM's "pick a winner" trial, with the impact of somatic mutationsLionel Adès, Nicolas Duployez, Agnes Guerci-Bresler, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 8, 2017
Prospective Evaluation of Magnetic Resonance Imaging and [<sup>18</sup>F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM StudyPhilippe Moreau, Michel Attal, Denis Caillot, et al.
Blood|October 25, 2017
R-CHOP 14 with or without radiotherapy in nonbulky limited-stage diffuse large B-cell lymphomaThierry Lamy, Gandhi Damaj, Pierre Soubeyran, et al.
Blood Advances|February 24, 2026
Risk stratification of low-dose cytarabine and venetoclax in patients with AML ineligible for intensive chemotherapyAndrew H Wei, Panayiotis Panayiotidis, Pau Montesinos, et al.
Cancer Medicine|December 9, 2022
Retrospective, real-life study of venetoclax plus azacitidine or low-dose cytarabine in French patients with acute myeloid leukemia ineligible for intensive chemotherapyLouise Laloi, Natacha Chaumard Billotey, Pierre-Yves Dumas, et al.
Pageof 11